Ratings Thermo Fisher Scientific Börse Stuttgart

Equities

TN8

US8835561023

Market Closed - Börse Stuttgart Other stock markets 14:54:03 2024-05-28 EDT			After market 16:00:00
525.1 ^EUR	-2.00%		527.1	+0.38%

05-24	Declaration of Voting Results by Thermo Fisher Scientific Inc	CI
05-22	Thermo Fisher Scientific Keeps Quarterly Dividend of $0.39 a Share, Payable July 15 to Shareholders of Record on June 14	MT

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The group shows a rather high level of debt in proportion to its EBITDA.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.68 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
THERMO FISHER SCIENTIFIC	+11.65%	223B	-
DANAHER CORPORATION	+11.83%	195B	B-
INTUITIVE SURGICAL, INC.	+18.87%	144B	B-
BOSTON SCIENTIFIC CORPORATION	+30.03%	111B	A-
SIEMENS HEALTHINEERS AG	+2.32%	65.19B	A-
EDWARDS LIFESCIENCES CORPORATION	+14.15%	53.02B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+2.68%	50.28B	B+
AGILENT TECHNOLOGIES, INC.	+6.60%	44.15B	A
GE HEALTHCARE TECHNOLOGIES INC.	+1.85%	36.45B	-
RESMED, INC.	+20.43%	31.33B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes